Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.

  title={Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.},
  author={Monique Freund and J‐P. Cazenave and Michael Courtney and Eric Degryse and Carolyn A. Roitsch and Andr{\'e} Bernat and Denis Delebassee and Ghislain Defreyn and Jean Pierre Maffrand},
  journal={Thrombosis and haemostasis},
  volume={63 2},
Antithrombotic potency of recombinant hirudins rHV2, rHV2-Lys47 and rHV2-Arg47 was studied in a model of experimental thrombosis induced by tissue factor in the rat. Venous thrombosis was induced by i.v. injection of 25 mg/kg tissue factor followed by stasis of the inferior vena cava. In this model natural recombinant hirudins, rHV2 and rHV2-Lys47 injected 5 min before thrombo-plastin totally inhibited thrombosis in the same micrograms range as heparin or natural hirudin extracted from leeches… Expand
Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time
These data show that, when administered as an intravenous infusion, argatroban is a potent antithrombotic agent in rat models of venous ‘mixed’ and arterial thrombosis, this effect can be obtained with a lower degree of systemic anticoagulation than with heparin in the arterial model, and argatro Ban has a lower haemorrhagic potential than that of he parin. Expand
Importance of platelets in experimental venous thrombosis in the rat.
Using the model of stasis and hypercoagulability, platelet activation played a major role in the development of venousThrombosis when the thrombogenitic stimulus was mild. Expand
A comparative study of recombinant hirudin and standard heparin in the Wessler model.
In the Wessler stasis model the fresh thrombus weight and a score as well as the circulating level of r-hirudin using a chromogenic substrate assay were used to determine the inhibitory effect of the drug. Expand
The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat
Findings suggest that danaparoid may be useful for the prevention of DIC and has less tendency to cause bleeding than dalteparin or heparin, probably as a result of its weaker ability to inhibit platelet aggregation. Expand
Antithrombotic and Platelet Activating Effects of Heparin in Prevention of Microarterial Thrombosis
This study demonstrates heparin‐induced platelet activation in vivo in conditions of platelet‐mediated thrombus formation, consistent with the concept of heparIn‐induced Platelet activation as one of the mechanisms explaining the limited effects of Heparin in preventing arterial thrombosis. Expand
Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model.
Because r-hirudin lacks effect on platelets, is a poor immunogen, does not require a plasma cofactor, and may not require an antagonist, it may provide an alternative anticoagulant to heparin in cardiopulmonary bypass. Expand
The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
The potential for optimized antithrombotic treatment in acute coronary syndromes when a GP IIb/IIIa antagonist (SR121787) is combined with an antithROMbin-dependent factor Xa inhibitor (SR90107/ORG31540) is suggested. Expand
Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans
  • P. Zancan, P. A. Mourão
  • Chemistry, Medicine
  • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • 2004
It is proposed that the different effects of fucosylated chondroitin sulfate and its carboxyl-reduced derivative on venous thrombosis may be related to adherence of the glycosaminoglycan to the vessel wall. Expand
Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Results suggest that thrombin-inhibiting drugs may increase the risk of bleeding, while darexaban may have potential as an orally available antithrombotic agent with a wide therapeutic window. Expand
Recombinant hirudin (HBW 023): Biological data of ten patients with severe venous thrombo‐embolism
Thrombin inhibition by rH‐hirudin at this dosage is only partial, which allows the generation of traces of thrombin needed for the feed‐back throm bin production generated by factor V and VIII activation. Expand